Navigation Links
Mindways QCT Comes of Age by Inclusion into FRAX
Date:5/15/2013

Austin, Texas (PRWEB) May 15, 2013

Measuring bone mineral density (BMD) to establish the presence of osteoporosis or low bone density is often performed using DXA; with the BMD measurement used in the FRAX® tool for fracture risk calculation. The inclusion of Mindways QCT bone density measurement into FRAX®, now offers patients and physicians an accurate and cost-effective alternative assessment method for determining osteoporotic fracture risk.

The World Health Organisation (WHO) Fracture Risk Assessment Tool(FRAX®) is a web-based tool used to calculate absolute fracture risk to ensure that people with the greatest chance of breaking a bone are treated. The tool was developed to help health care providers determine the chances of a patient breaking their hip or another major bone within a ten year period. Health care providers enter information about a patient’s hip BMD together with certain other risk factors for osteoporosis to determine absolute fracture risk.

Mindways QCT Pro™ software performs bone densitometry exams for both the lumbar spine and hip from a standard CT scan using low-dose scan protocols, comparable to the radiation exposure of a mammogram. While spine measurements are made in the trabecular bone only and offer exceptional sensitivity to BMD changes, QCT Pro™ also produces DXA-equivalent BMD measurement and T-scores at the hip that are interpreted the same way as DXA reports.

Unlike the patient positioning requirements of other technologies, the hips do not need to be rotated for a 3D QCT scan, enhancing comfort for patients with arthritic hips. QCT scans and bone density
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Kansas Bioscience Authority Announces FY11 Outcomes of $207 Million
2. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
3. Cepheid Welcomes Senior Vice President of Human Resources
4. Adeona Becomes Synthetic Biologics, Inc.
5. Good Shepherd Rehabilitation Network Becomes Third Health-Care Organization in U.S. to Have Ekso Exoskeleton
6. The 14th Annual LOréal-Unesco Awards or Women on Science: From March 26 to March 29, Paris Welcomes and Honours Tomorrows Scientific Talents
7. OrbusNeichs Combo Dual Therapy Stent™ Demonstrates Favorable Clinical and Safety Outcomes at 12-Month Follow-Up
8. In Comes the Non-Toxic Rust Remover; Rusterizer Presents Its Rust Removal Product Made With Natural Ingredients
9. Spiral Flow(TM) Grafts Enhance Patient Outcomes - New Paper Published in the Prestigious Annals of Vascular Surgery
10. Agendia Welcomes Dr. Mark Gittleman to Expanding Medical Advisory Board
11. United States Rocket Academy Welcomes XCOR Aerospace to Texas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... N.J. , July 28, 2015  Moerae ... second Phase 1 clinical trial with MMI-0100, a ... is being developed for pulmonary disorders characterized by ... United Kingdom , is a ... further evaluating the safety and tolerability of MMI-0100 ...
(Date:7/28/2015)... , July 28, 2015 /PRNewswire/ - Aeterna Zentaris ... announced that it has granted to German life ... the development and commercialization of biotechnology (collectively, the ... recombinant oral allogenic tumor vaccine technology (the "Technology"), ... prostate cancer which is ready to enter a ...
(Date:7/28/2015)... -- Faced with increasing challenges such as costly treatments ... the global healthcare industry today is gradually transforming ... or significantly changing the course of a disease, ... medicine as a viable alternative. Regenerative ... with the potential to resolve unmet medical needs ...
(Date:7/27/2015)... 2015 /PRNewswire/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" ... products for the treatment of cancer, today provides the ... has closed a $1,000,000 unit offering private placement.  This ... of the Company at a price of $0.06 per ... and one common share purchase warrant.  Each whole warrant ...
Breaking Biology Technology:Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 4Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 5Quest PharmaTech Closes $1,000,000 Private Placement 2
... 19, 2011 Generex Biotechnology Corporation,s (OTCBB: GNBT) ... ( www.antigenexpress.com ), today announced that AE37, a ... prostate, and other cancers, is reviewed in the ... Biological Therapy , a peer-reviewed, international journal publishing ...
... Biopharmaceuticals (Nasdaq: KERX ) today announced completion ... its Phase 3 registration program of Zerenex™, the Company,s ... serum phosphorus levels, or hyperphosphatemia, in patients with end-stage ... registration program, which is being conducted pursuant to a ...
... Sept. 19, 2011 A growing chorus of patients and ... agreeing to more radical surgeries to treat prostate cancer. ... Florida urologist Dr. Bert Vorstman, a nationally recognized prostate cancer ... treatment. In an article in a major Florida ...
Cached Biology Technology:Antigen Express Cancer Vaccine Highlighted in Expert Opinion on Biological Therapy 2Antigen Express Cancer Vaccine Highlighted in Expert Opinion on Biological Therapy 3Antigen Express Cancer Vaccine Highlighted in Expert Opinion on Biological Therapy 4Antigen Express Cancer Vaccine Highlighted in Expert Opinion on Biological Therapy 5Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study 2Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study 3Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study 4Some Patients Paying for Their Prostate Cancer Surgery for the Rest of Their Lives 2Some Patients Paying for Their Prostate Cancer Surgery for the Rest of Their Lives 3
(Date:7/23/2015)... Mass., July 23, 2015 Aware, Inc. (NASDAQ: ... today reported financial results for its second quarter ended June ... of 2015 was $4.5 million, a decrease of 33% compared ... income in the second quarter of 2015 was $0.3 million, ... or $0.04 per diluted share, in the same period a ...
(Date:7/21/2015)... July 21, 2015 Passwords have proven ... in the recent U.S. Office of Personnel Management ... the infosec conundrum, but developers and end-users are ... address this dilemma, Biometrics-as-a-Service provider HYPR Corp. announced ... SDK for third party integration. ...
(Date:7/9/2015)... Calif. , July 9, 2015  Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... Thursday, July 30, 2015 after the close of market. ... analysts and investors at 2:00 p.m. PT (5:00 p.m. ... To participate on the live call, analysts ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
... Network (IAN), with support from leading autism advocacy groups, ... of wandering and elopement, or escaping, among individuals with ... ASD to wander or "bolt" puts them at risk ... this critical safety issue is lacking. Since ...
... superlative by being able to capture the "evanescent" light ... never travel far enough to be "seen" by a ... of applications, depending upon the form of light ... most have been made from elaborate artificial constructs known ...
... launched a collaborative project to develop and evaluate new ... AvecNet is a five year, 12 million project ... the European Union,s Seventh Framework programme. Because malaria ... to combating the disease. Wide scale use of ...
Cached Biology News:Why do children with autism wander and bolt from safe places? 2Berkeley Lab researchers make first perovskite-based superlens for the infrared 2Berkeley Lab researchers make first perovskite-based superlens for the infrared 3Berkeley Lab researchers make first perovskite-based superlens for the infrared 4Berkeley Lab researchers make first perovskite-based superlens for the infrared 5€12 million ($16.9 million) project to develop new tools for malaria control 2
SDS-OutT Precipitation Reagent...
... The new FLA-5000 imaging system ... radioisotopic samples as large as ... as low as 25 microns. ... for protein electrophoresis in the ...
SDS-OutT SDS Precipitation Reagent...
... Ideal for staining westerns and includes stickers ... Pour spouts in each corner facilitate pouring ... be used for identification. Lid is designed ... for staining several gels simultaneously. Lid also ...
Biology Products: